GPR133 flip reverses osteoporosis in mice

Osteoporosis drugs usually work by slowing bone loss, nudging bone formation, or both. But the field still has a basic problem — it does not have many clean new targets that tell bone to rebuild itself in a durable way. That is why this GPR133 result matters. A team from Leipzig University and Shandong University says a little-known receptor on bone-forming cells acts like a control switch for bone strength, and a compound called AP503 pushed that switch hard enough to reverse osteoporosis-like damage in mice. ### What is GPR133? GPR133 — also called ADGRD1 — is a receptor on the cell surface. It belongs to the adhesion GPCR family, which is a medically important receptor class but still underused in drug development. Human genetic studies had already linked variants near this receptor to bone mineral density and height, which is what made it worth chasing in the first place. ### Why did researchers think it mattered for bone? (nature.com) They knocked the gene out in mice. The result was not subtle. Mice missing Gpr133, either broadly or specifically in osteoblasts, developed reduced cortical bone mass and abnormal trabecularization in the femur and vertebrae — basically a bone pattern that looks a lot like osteoporosis. The paper ties that to weaker osteoblast function, which then lets bone-resorbing osteoclast activity rise. (nature.com) ### What changed in this study? The big step was not just showing the receptor matters. It was showing that researchers could activate it from the outside with a small molecule called AP503. In cell and animal experiments, AP503 increased osteoblast function and differentiation, and in the mouse ovariectomy model — the standard model for postmenopausal bone loss — it significantly alleviated osteoporosis-like changes. (nature.com) ### How is this supposed to work? Bone is constantly being rebuilt. Osteoblasts lay new bone down. Osteoclasts chew old bone away. GPR133 seems to sit near the top of that balance. The paper says the receptor is activated by two inputs together — interaction with PTK7 and mechanical force — and then signals through cAMP and β-catenin to support osteoblast differentiation. Leipzig’s summary adds the practical version: turn on GPR133 and you stimulate bone-building cells while also holding bone-resorbing cells back. (nature.com) ### Is this the only GPR133 bone paper? No — and that is part of why the story is interesting. A separate 2025 Science Advances paper hit the same receptor from the osteoclast side with another agonist, GL64. That team found ADGRD1 activation suppressed osteoclast formation through a cAMP-PKA-NFATC1 pathway and prevented bone loss in an ovariectomy mouse model. So two groups are converging on the same receptor, but from different cell types and with different compounds. (nature.com) ### Why is that convergence a big deal? Because osteoporosis is a balance problem. Many therapies lean mainly on one side of the seesaw. What makes GPR133 intriguing is that it may influence both sides at once — helping osteoblasts build and making it harder for osteoclasts to overdo breakdown. That does not prove a future drug will work in people, but it does make the biology look less like a fluke. (science.org) ### What is the catch? This is still mouse work. AP503 is an experimental agonist, not a human medicine. Researchers still need pharmacology, toxicity, dosing, durability, and off-target data, plus proof that the same pathway behaves usefully in human bone. And because GPR133 belongs to a receptor family involved in many tissues, safety is the part that can turn a clever mechanism into a dead end. (nature.com) ### Bottom line The real news is not “osteoporosis cured.” It is that a weird, previously obscure receptor now looks like a plausible bone-rebuilding target. In mice, flipping GPR133 with AP503 made weak bones stronger. If that survives the long trip into human drug development, this could become a genuinely new way to treat bone loss. (nature.com)